Core Insights - Biotricity Inc. and B-Secur have partnered to create an advanced, device-neutral platform for integrated heart monitoring, enhancing capabilities for healthcare providers and diagnostic facilities [1][2] - The partnership aims to address critical gaps in cardiac care delivery, improving accessibility and efficiency for both healthcare providers and patients [3][5] Company Overview - Biotricity is focused on reforming the healthcare market through remote monitoring and chronic care management, providing diagnostic solutions for chronic conditions [6] - B-Secur specializes in biosensing technology, offering medical-grade ECG data for faster diagnosis and management, and is ISO 13485:2016 certified [5] Industry Context - With 90% of U.S. adults at risk of cardiovascular disease (CVD) and a projected shortage of up to 124,000 physicians by 2034, there is an urgent need for scalable solutions for early detection and intervention [3] - The financial burden of CVD is expected to triple to $1.8 trillion by 2050, highlighting the importance of proactive cardiac management [3][4]
Biotricity and B-Secur Partner to Launch the Most Comprehensive Device-Neutral Ambulatory Cardiac Monitoring Platform